Cardiac contractility modulation therapy in patients with implanted cardiac resynchronization therapy: results of the 2 year follow-up

Aim. Cardiac contractility modulation (CCM) is a device therapy for patients with heart failure with reduced ejection fraction (HFrEF), most of the data on its programming are concerned patients with narrow QRS and of limited follow up. Our aim was to propose programming approach for Optimizer device in setting of wide QRS complex and fragmented ventricular local activation.

Methods. We enrolled 11 patients with HFrEF (median age, 8 males, median NYHA class 3) and LBBB-related wide QRS complex, who underwent Optimizer™ device implantation. Three patients got Optimizer™ IV system and eight patients were implanted Optimizer™ Smart. Ten patients were previously implanted with CRT-D due to HFrEF and LBBB; one patient received CRT-D after Optimizer™ implantation.

Results. During the implantation procedure ventricular local sense (LS) channel signal fragmentation was detected in all patients. In five patients signal detection was optimized by lead relocation. In six patients LS signal sensitivity limitations were resolved by programming. At two-year follow-up survival 4 patients died of noncardiac causes (1 intracranial hemorrhage, 1 gastrointestinal bleeding and 2 - terminal kidney failure). At 12-month follow-up we observed a non-significant improvement in 6-minute walking distance (300 vs 305, p=0.093), NYHA class (2.75 vs 2, p=0.085), MLHF score (53 vs 42, p=0.109) and left ventricular ejection fraction (LVEF) (30 vs 33.5, p=0.212).

Conclusion. CCM system implantation is feasible and safe in patients with HFrEF and LBBB-related wide QRS complex. Device programming maneuvers can resolve the challenges of ventricular local signal detection in these patients.

1. Imai M, Rastogi S, Gupta RC, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol. 2007;49(21): 2120-8. https://doi.org/10.1016/J.JACC.2006.10.082.

2. Stix G, Borggrefe M, Wolpert C, et al. FT Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J. 2004;25(8): 650-5. https://doi.org/10.1016/j.ehj.2004.02.027.

3. Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29: 1019-28. https://doi.org/10.1093/eurheartj/ehn127.

4. Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161(2):3 29-337.e2. https://doi.org/10.1016/j.ahj.2010.10.025.

5. Abraham WT, Lindenfeld J, Reddy VY, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation in Patients With Moderately Reduced Left Ventricular Ejection Fraction and a Narrow QRS Duration. J Card Fail. 2015;21(1):16-23. https://doi.org/10.1016/j.cardfail.2014.09.011.

6. Nadeem M, Tariq EF, Aslam HM, et al. All-Cause Mortality Outcomes of Usage of Cardiac Contractility Modulation in Patients With Dilated Cardiomyopathy Ineligible for Cardiac Re-Synchronization Therapy: An Updated Meta-Analysis of Randomized Controlled Trials. Cureus 2020;12(9). https://doi.org/10.7759/cureus.10627.

7. Giallauria F, Parlato A, di Lorenzo A, et al. Cardiac Contractility Modulation in Patients with Heart Failure with Reduced Left Ventricular Ejection Fraction. Hearts. 2021;2(1): 156-69. https://doi.org/10.3390/hearts2010013.

8. Nägele H, Behrens S, Eisermann C. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Europace. 2008;10(12): 1375-80. https://doi.org/10.1093/europace/eun257.

9. Kuschyk J, Nägele H, Heinz-Kuck K, et al. Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT). Int J Cardiol. 2019;277:173-7. https://doi.org/10.1016/j.ijcard.2018.10.086.

10. Sieniewicz BJ, Gould J, Porter B, et al. Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions. Heart Fail Rev. 2019;24(1): 41-54. https://doi.org/10.1007/S10741-018-9734-8/FIGURES/5.

11. Auricchio A, Fantoni C, Regoli F, et al. Characterization of Left Ventricular Activation in Patients with Heart Failure and Left Bundle-Branch Block. Circulation. 2004;109(9): 1133-9. https://doi.org/10.1161/01.CIR.0000118502.91105.F6.

12. Röger S, Schneider R, Rudic B, et al. Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation. Europace. 2014;16(8): 1205-9. https://doi.org/10.1093/EUROPACE/EUU050.